Stock 688739 LIAONING CHENGDA BIOTECHNOLOGY CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Liaoning Chengda Biotechnology Co.,Ltd.

Equities

688739

CNE100004ZP2

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 07/06/2024 am IST 		5-day change 1st Jan Change
25.99 CNY +0.15% Intraday chart for Liaoning Chengda Biotechnology Co.,Ltd. -4.76% -20.06%
20/05 Wall Street Cues, Central Bank Outlooks Lift Asian Stock Markets MT
29/04 Liaoning Chengda Biotechnology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 12,668 13,539 10,730 - -
Enterprise Value (EV) 1 12,668 13,539 10,730 10,730 10,730
P/E ratio 17.7 x - - - -
Yield - - - - -
Capitalization / Revenue - 7.74 x 6.06 x 5.75 x 5.28 x
EV / Revenue - 7.74 x 6.06 x 5.75 x 5.28 x
EV / EBITDA - 19.3 x 17.3 x 16.6 x 15.6 x
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - - 1.11 x 1.07 x 1.04 x
Nbr of stocks (in thousands) 4,16,450 4,16,450 4,12,856 - -
Reference price 2 30.42 32.51 25.99 25.99 25.99
Announcement Date 24/02/23 23/02/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - 1,750 1,771 1,867 2,034
EBITDA 1 - 701.7 620 645 689
EBIT 1 - - 543 568 609
Operating Margin - - 30.66% 30.42% 29.94%
Earnings before Tax (EBT) - - - - -
Net income 714.8 - - - -
Net margin - - - - -
EPS 1.720 - - - -
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 24/02/23 23/02/24 - - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - 4.84% 4.8% 4.8% 5%
ROA (Net income/ Total Assets) - 4.66% 4.5% 4.6% 4.7%
Assets - - - - -
Book Value Per Share 1 - - 23.40 24.20 25.10
Cash Flow per Share - - - - -
Capex 2 - 552 148 149 170
Capex / Sales - 31.54% 8.36% 7.98% 8.36%
Announcement Date 24/02/23 23/02/24 - - -
1CNY2CNY in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
25.99 CNY
Average target price
32 CNY
Spread / Average Target
+23.12%
Consensus

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
LIAONING CHENGDA BIOTECHNOLOGY CO.,LTD. Stock Liaoning Chengda Biotechnology Co.,Ltd.
-20.06% 1.48B
CSL LIMITED Stock CSL Limited
+0.82% 91.94B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-1.32% 38.74B
UCB Stock UCB
+64.70% 26.66B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-13.43% 15.32B
INCYTE CORPORATION Stock Incyte Corporation
-5.91% 13.3B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.38% 11.65B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+173.10% 10.37B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-49.84% 10.12B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+2.47% 9.06B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 688739 Stock
  4. Financials Liaoning Chengda Biotechnology Co.,Ltd.